Jean Pierre Lindenmayer

Summary

Affiliation: Nathan Kline Institute
Country: USA

Publications

  1. doi request reprint A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities
    Jean Pierre Lindenmayer
    New York University School of Medicine, 600 East 125th Street, New York, NY 10035, USA
    Schizophr Res 147:241-52. 2013
  2. pmc Improving social cognition in schizophrenia: a pilot intervention combining computerized social cognition training with cognitive remediation
    Jean Pierre Lindenmayer
    Psychopharmacology Research Department, Manhattan Psychiatric Center, 600 E 125 St, Ward s Island, NY 10035, USA
    Schizophr Bull 39:507-17. 2013
  3. doi request reprint Relationship between metabolic syndrome and cognition in patients with schizophrenia
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, Wards Island, NY, United States
    Schizophr Res 142:171-6. 2012
  4. ncbi request reprint The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center Nathan Kline Institute for Psychiatric Research, New York University, New York, NY, USA
    Psychopharmacol Bull 41:11-35. 2008
  5. doi request reprint Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia
    Jean Pierre Lindenmayer
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Clin Schizophr Relat Psychoses 5:185-92. 2012
  6. pmc Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
    Ibrahim Turkoz
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey, USA
    BMC Psychiatry 11:21. 2011
  7. pmc Item response analysis of the Positive and Negative Syndrome Scale
    Darcy A Santor
    School of Psychology, University of Ottawa, Ottawa, Canada, and The Provincial Centre of Excellence for Child and Youth Mental Health, Ottawa, Ontario, Canada
    BMC Psychiatry 7:66. 2007
  8. doi request reprint A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, 600 East 125th St, Wards Island, NY 10035, USA
    Psychiatr Serv 59:241-7. 2008
  9. ncbi request reprint Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, New York University of Medicine, New York, NY, USA
    Eur Neuropsychopharmacol 17:138-44. 2007
  10. doi request reprint Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response
    Jean Pierre Lindenmayer
    New York University School of Medicine, New York, N Y 10035, USA
    J Clin Psychiatry 70:990-6. 2009

Detail Information

Publications64

  1. doi request reprint A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities
    Jean Pierre Lindenmayer
    New York University School of Medicine, 600 East 125th Street, New York, NY 10035, USA
    Schizophr Res 147:241-52. 2013
    ....
  2. pmc Improving social cognition in schizophrenia: a pilot intervention combining computerized social cognition training with cognitive remediation
    Jean Pierre Lindenmayer
    Psychopharmacology Research Department, Manhattan Psychiatric Center, 600 E 125 St, Ward s Island, NY 10035, USA
    Schizophr Bull 39:507-17. 2013
    ....
  3. doi request reprint Relationship between metabolic syndrome and cognition in patients with schizophrenia
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, Wards Island, NY, United States
    Schizophr Res 142:171-6. 2012
    ..We hypothesized that patients with MetS would be associated with more impaired cognitive performance...
  4. ncbi request reprint The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center Nathan Kline Institute for Psychiatric Research, New York University, New York, NY, USA
    Psychopharmacol Bull 41:11-35. 2008
    ..This study aimed to demonstrate efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) versus placebo in patients with acute schizophrenia...
  5. doi request reprint Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia
    Jean Pierre Lindenmayer
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Clin Schizophr Relat Psychoses 5:185-92. 2012
    ....
  6. pmc Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
    Ibrahim Turkoz
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey, USA
    BMC Psychiatry 11:21. 2011
    ..To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology...
  7. pmc Item response analysis of the Positive and Negative Syndrome Scale
    Darcy A Santor
    School of Psychology, University of Ottawa, Ottawa, Canada, and The Provincial Centre of Excellence for Child and Youth Mental Health, Ottawa, Ontario, Canada
    BMC Psychiatry 7:66. 2007
    ....
  8. doi request reprint A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, 600 East 125th St, Wards Island, NY 10035, USA
    Psychiatr Serv 59:241-7. 2008
    ..This study evaluated the feasibility and efficacy of a cognitive remediation program in improving cognitive and work functioning for intermediate- to long-stay psychiatric inpatients...
  9. ncbi request reprint Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, New York University of Medicine, New York, NY, USA
    Eur Neuropsychopharmacol 17:138-44. 2007
    ..It is concluded that treatment with long-acting injectable risperidone for 1 year or longer appeared to be safe and well tolerated in patients with schizophrenia or schizoaffective disorder...
  10. doi request reprint Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response
    Jean Pierre Lindenmayer
    New York University School of Medicine, New York, N Y 10035, USA
    J Clin Psychiatry 70:990-6. 2009
    ..To examine the impact of medication nonadherence on treatment outcome in schizophrenia and potential risk factors for nonadherence...
  11. doi request reprint Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia
    Jean Pierre Lindenmayer
    New York University School of Medicine, 530 1st Ave New York, NY 10016, USA
    Schizophr Res 125:267-77. 2011
    ..Given these mixed results we examined whether galantamine compared to adjunctive placebo may improve cognitive functions in patients treated concomitantly with a long acting atypical antipsychotic...
  12. ncbi request reprint Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone
    Jean Pierre Lindenmayer
    New York University Medical Center, New York, USA
    Int Clin Psychopharmacol 20:213-21. 2005
    ..30; endpoint = 7.70; P<0.0001 versus baseline). These findings may positively affect patient and clinician attitudes towards long-term therapy with long-acting injectable risperidone...
  13. doi request reprint Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, New York University of Medicine, New York, NY, USA
    Psychopathology 41:264-70. 2008
    ....
  14. ncbi request reprint Treatment refractory schizophrenia
    J P Lindenmayer
    Psychopharmacology Research Unit, Manhattan Psychiatric Center Nathan Kline Institute for Psychiatric Research, New York, NY 10035, USA
    Psychiatr Q 71:373-84. 2000
    ..We review studies with augmentation strategies which remain difficult to interpret given the open label and uncontrolled nature of most of these studies...
  15. ncbi request reprint Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
    Jean Pierre Lindenmayer
    Nathan Kline Institute, Orangeburg, N Y, USA
    J Clin Psychiatry 65:551-6. 2004
    ..We are exploring whether this expanded clinical efficacy can also be seen in patients with treatment-resistant schizophrenia...
  16. ncbi request reprint Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial
    J P Lindenmayer
    Psychopharmacology Research Unit, Manhattan Psychiatric Unit, Manhattan Psychiatric Center, Wards Island, New York 10035, USA
    J Clin Psychopharmacol 21:448-53. 2001
    ..However, a trial with olanzapine can be recommended in these patients before moving to augmentation strategies, given the lack of proven alternatives and the observation that 16.7% of patients reached the response criteria...
  17. ncbi request reprint Pharmacological treatment strategies for schizophrenia
    J P Lindenmayer
    Psychopharmacology Research Unit, Manhattan Psychiatric Center, Wards Island, NY 10035, USA
    Expert Rev Neurother 4:705-23. 2004
    ..Finally, the results of recent meta-analyses comparing the effects of atypical versus typical compounds will be critically reviewed and remaining gaps in the current pharmacotherapy of schizophrenia will be explored...
  18. ncbi request reprint Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study
    Jean Pierre Lindenmayer
    Psychopharmacology Research Unit, Manhattan Psychiatric Center, Wards Island, NY 10035, USA
    J Clin Psychiatry 63:931-5. 2002
    ....
  19. ncbi request reprint Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
    Jean Pierre Lindenmayer
    Nathan Kline Institute fo Psychiatric Research, New York, NY 10035, USA
    Am J Psychiatry 160:290-6. 2003
    ....
  20. doi request reprint A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, Psychopharmacology Research Program, New York, NY, USA
    J Clin Psychopharmacol 31:160-8. 2011
    ..In conclusion, quetiapine at 1200 mg/d, although reasonably tolerated, did not confer any advantages over quetiapine at 600 mg/d among patients who had failed to demonstrate an adequate response to a prospective 4-week trial of 600 mg/d...
  21. ncbi request reprint The InterSePT scale for suicidal thinking reliability and validity
    J P Lindenmayer
    New York University School of Medicine, New York, NY, USA
    Schizophr Res 63:161-70. 2003
    ..We report the psychometric characteristics of this new scale based on two studies...
  22. ncbi request reprint An excitement subscale of the Positive and Negative Syndrome Scale
    Jean Pierre Lindenmayer
    Department of Psychiatry, New York University School of Medicine, and Manhattan Psychiatric Center, Wards Island Complex, New York, NY, USA
    Schizophr Res 68:331-7. 2004
    ....
  23. ncbi request reprint Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    Am J Psychiatry 159:255-62. 2002
    ....
  24. ncbi request reprint Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Am J Psychiatry 159:1018-28. 2002
    ....
  25. ncbi request reprint Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Biol Psychiatry 52:701-7. 2002
    ....
  26. ncbi request reprint Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    J Clin Psychopharmacol 24:225-8. 2004
    ..Clozapine appears to have superior antiaggresive effects in treatment-resistant patients; this superiority develops after the patient has been exposed to an adequate dose regimen...
  27. doi request reprint Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study
    Robert C Smith
    Department of Psychiatry, NYU Medical School, Hewlett, NY 11557, USA
    J Clin Psychiatry 70:1501-13. 2009
    ..Randomized prospective studies of metabolic effects during treatment with these drugs may provide results that are more informative...
  28. ncbi request reprint Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder
    Karen A Nolan
    Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Psychiatr Res 39:109-15. 2005
    ..These findings in chronic, treatment resistant inpatients support the view that positive symptoms may lead to aggression...
  29. ncbi request reprint Antipsychotic-induced weight gain and therapeutic response: a differential association
    Pal Czobor
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    J Clin Psychopharmacol 22:244-51. 2002
    ..These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain...
  30. ncbi request reprint Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan Kline Institute, Orangeburg, NY 10982, USA
    J Clin Psychiatry 65:57-61. 2004
    ....
  31. doi request reprint Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study
    Robert C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY 11557, USA
    Schizophr Res 120:204-9. 2010
    ..We present results of a randomized prospective study of lipid metabolism and metabolic syndrome in chronic schizophrenic patients using both fasting and post-prandial lipid measures...
  32. ncbi request reprint COMT158 polymorphism and hostility
    Jan Volavka
    Nathan Kline Institute, Orangeburg, New York 10982, USA
    Am J Med Genet B Neuropsychiatr Genet 127:28-9. 2004
    ..The Met-Met homozygotes (N = 7) were found to have significantly higher levels of hostility than the other patients (N = 53). The hypothesis was thus supported. The finding should be replicated in a larger sample...
  33. pmc Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder
    Matthew J Hoptman
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatry Res 140:133-45. 2005
    ..Larger left OFC gray matter volumes and larger OFC white matter volumes bilaterally were associated with greater levels of aggression. These findings are discussed in the context of potential iatrogenic effects...
  34. doi request reprint Outcome evaluation of a structured educational wellness program in patients with severe mental illness
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, Department of Psychiatry, New York University School of Medicine, Manhattan, New York, New York, USA
    J Clin Psychiatry 70:1385-96. 2009
    ....
  35. ncbi request reprint A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, Psychopharmacology Research Unit, New York, NY 10035, USA
    J Clin Psychiatry 68:368-79. 2007
    ....
  36. ncbi request reprint Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
    John M Kane
    The Zucker Hillside Hospital, New York, NY 11004, USA
    Am J Psychiatry 160:1125-32. 2003
    ..The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia...
  37. ncbi request reprint Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics
    Jean Pierre Lindenmayer
    Manhattan Psychiatric Center, New York University School of Medicine, New York, NY 10035, USA
    J Clin Psychiatry 65:1084-9. 2004
    ..The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications...
  38. ncbi request reprint Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Clin Psychiatry 66:1512-6. 2005
    ..The purpose of this article is to review the past and present dosing patterns of quetiapine for the treatment of schizophrenia...
  39. ncbi request reprint A cognitive, behaviorally based program for patients with persistent mental illness and a history of aggression, crime, or both: structure and correlates of completers of the program
    Kathy Yates
    New York University School of Medicine and Manhattan Psychiatric Center, Ward s Island Complex, NY 10035, USA
    J Am Acad Psychiatry Law 33:214-22. 2005
    ..In comparison with the 91 who did not complete the program, those who did were less cognitively impaired and less impulsive. We present a new, intensive treatment program and define the predictors of successful completion of the program...
  40. ncbi request reprint Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review
    Carlos Saavedra-Velez
    Department of Psychiatry, New York University Medical Center, New York, NY, USA
    J Clin Psychiatry 70:104-12. 2009
    ....
  41. doi request reprint Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder
    Robert C Smith
    Department of Psychiatry, New York University Medical School, NY 11557 0316, United States
    Schizophr Res 110:149-55. 2009
    ..We present the first prospective quantitative data on the effects of varenicline on cognitive function, cigarette smoking, and psychopathology in a small sample of schizophrenic patients...
  42. pmc Cognitive and symptomatic predictors of functional disability in schizophrenia
    Syed Shamsi
    Department of Psychiatry, Division of Psychiatry Research, Glen Oaks, NY 11004, United States
    Schizophr Res 126:257-64. 2011
    ..Few studies have assessed the relationship between functional outcomes and the MATRICS consensus cognition battery (MCCB), which will be central to future clinical trials of cognitive enhancing agents...
  43. pmc Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Neuropsychopharmacology 36:1289-95. 2011
    ..However, given the lack of evidence to guide clinicians and patients when clozapine does not work well, more controlled trials of innovative strategies are warranted...
  44. pmc Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder
    Matthew J Hoptman
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    J Neuropsychiatry Clin Neurosci 18:509-15. 2006
    ..The relationship between aggression and caudate volumes may be related to the iatrogenic effects of long-term treatment with typical antipsychotic agents or to a direct effect of schizophrenic processes on the caudate...
  45. ncbi request reprint A new Integrated Negative Symptom structure of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia using item response analysis
    Anzalee Khan
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States ProPhase LLC, 3 Park Avenue, 37th Floor, New York, NY 10016, United States Manhattan Psychiatric Center, 1 Wards Island Complex, NY, NY 10035, United States Electronic address
    Schizophr Res 150:185-96. 2013
    ....
  46. doi request reprint Normal pressure hydrocephalus presenting as Othello syndrome: case presentation and review of the literature
    Anna Yusim
    Department of Psychiatry, New York University Medical Center, New York, NY 10128, USA
    Am J Psychiatry 165:1119-25. 2008
  47. pmc Use of non-parametric item response theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS)
    Anzalee Khan
    Fordham University, Department of Psychometrics, Bronx, NY, USA
    BMC Psychiatry 11:178. 2011
    ....
  48. ncbi request reprint Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients
    Robert C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY 11557, USA
    Int J Neuropsychopharmacol 8:183-94. 2005
    ....
  49. doi request reprint Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS)
    Vladan Novakovic
    Department of Psychiatry, Mount Sinai School of Medicine, Manhattan Psychiatric Center, New York, NY, USA
    Clin Neuropharmacol 36:59-62. 2013
    ..This proposal seeks to review data regarding all currently available LAI antipsychotics to determine if a significant association exists between these depot formulations and the development of PDSS...
  50. pmc Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review
    Rachel Neuhut
    Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    J Child Adolesc Psychopharmacol 19:415-22. 2009
    ..The purpose of this report is to examine the published cases of NMS in children and adolescents receiving atypical antipsychotic medication and review early warning symptoms, risk factors, and treatment in this population...
  51. ncbi request reprint Clozapine augmentation with aripiprazole for negative symptoms
    Laura A Clarke
    J Clin Psychiatry 67:675-6. 2006
  52. ncbi request reprint Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
    Daniel E Casey
    J Clin Psychiatry 65:4-18; quiz 19-20. 2004
  53. ncbi request reprint Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment
    Vincenzo De Luca
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R 30, Toronto, Ont, Canada M5T 1R8
    Pharmacol Res 51:381-4. 2005
    ..Our results suggest that the novel polymorphism may not play a major role in antipsychotic response...
  54. ncbi request reprint Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia
    Daniel J Muller
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    Eur Neuropsychopharmacol 15:525-31. 2005
    ..8 to 7%. Our results further suggest that this effect is only attributable to Caucasians when compared to African-Americans. Moreover, our findings point to the role of intracellular mechanisms in antipsychotic response...
  55. ncbi request reprint Improved long-term outcome with long-acting risperidone treatment of chronic schizophrenia with prior partial response
    Jean Pierre Lindenmayer
    McLean Hospital
    J Psychiatr Pract 12:55-7. 2006
  56. ncbi request reprint Course of patients with histories of aggression and crime after discharge from a cognitive-behavioral program
    Michael Kunz
    Huntington Department of Veterans Affairs Medical Center, West Virginia, USA
    Psychiatr Serv 55:654-9. 2004
    ..A long-term behaviorally based cognitive skills program was developed and administered to a group of such high-risk inpatients. The authors report the results of a postdischarge follow-up of this group...
  57. ncbi request reprint Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients
    Andrya M Crossman
    J Clin Psychiatry 67:1158-9. 2006
  58. ncbi request reprint The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients
    Larry Alphs
    Schizophr Bull 30:577-86. 2004
    ..Because of the complexity of the design issues, a steering committee, suicide monitoring board, and publication committee were established to assist with their management...
  59. ncbi request reprint Measuring efficacy of polypharmacy in schizophrenic inpatients
    Jean Pierre Lindenmayer
    J Clin Psychiatry 65:1148; author reply 1148. 2004
  60. ncbi request reprint The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia
    Daniel J Muller
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R30, Toronto, Ont M5T 1R8, Canada
    Neurosci Lett 379:81-9. 2005
    ..Weight changes do not seem to be associated with polymorphism of the SNAP-25 gene, however, replication in independent samples is warranted...
  61. doi request reprint Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
    ....
  62. ncbi request reprint Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial
    Marc Bourgeois
    Psychopathology Research Laboratory, University of Bordeaux, 3 ter, Place de la Victoire, 33076 Bordeaux, France
    Am J Psychiatry 161:1494-6. 2004
    ..Schizophrenia is characterized by high suicide risk and low awareness of disorder. Although awareness has benefits for medication compliance and clinical outcome, it is unclear how it may relate to suicide risk in this population...
  63. ncbi request reprint Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation
    Jan Volavka
    Schizophr Res 76:127-9. 2005
  64. ncbi request reprint Efficacy of molindone in treatment-refractory agitated schizophrenia: three case reports
    Michael Ciranni
    J Clin Psychiatry 69:1018-9. 2008